Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Aurinia Pharmaceuticals Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Kevin Tang has been appointed as Chief Executive Officer of Aurinia Pharmaceuticals effective March 23, 2026, transitioning from his role as Chair of the Board. This leadership change signals a strategic shift and may impact the company's future business direction and operational priorities.
Key Takeaways
Kevin Tang, age 59, assumes the CEO role with extensive life sciences sector experience and prior leadership at La Jolla Pharmaceutical and Odonate Therapeutics
Tang previously served as Chair of the Board since 2024 and currently leads Tang Capital Management, LLC, indicating continuity in strategic vision
2 more takeaways
Related Filings (2)
2 more filings from Aurinia Pharmaceuticals Inc. in the last 90 days